Anti-PRAME/HLA-A*0201 TCR T-cell therapy (T-Knife Therapeutics)

N/A

Report date: 2024/03/27 17:50:09

Base Information

Drug NameAnti-PRAME/HLA-A*0201 TCR T-cell therapy (T-Knife Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma antigen preferentially expressed in tumors modulatorsHLA class I histocompatibility antigen, A alpha chain modulators
TargetsMelanoma antigen preferentially expressed in tumorsHLA class I histocompatibility antigen, A alpha chain
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesT-knife Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesT-knife Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A